dc.contributor.author | Alizadeh, AA | |
dc.contributor.author | Hamzeh-Mivehroud, M | |
dc.contributor.author | Farajzadeh, M | |
dc.contributor.author | Dastmalchi, S | |
dc.date.accessioned | 2018-08-26T08:57:22Z | |
dc.date.available | 2018-08-26T08:57:22Z | |
dc.date.issued | 2017 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/54565 | |
dc.description.abstract | The aim of this study was to identify novel TNF-? blocking peptide(s) using phage display technology. Two novel 7-mer TNF-? binding peptides P51 and P52 with Kd values of 1.47 and 0.51 nM were identified. Phage particles displaying P51 and P52 peptides at 0.318 nM concentration prevent cytotoxic effect of TNF-? on L929 cells by 8.2% and 16.15%, respectively. Synthesized P51 and P52 peptides also inhibited TNF-? induced cytotoxicity with IC50 values of 25.15 آ± 2.18 and 7.08 آ± 2.24 ?M, respectively. The result of RT-PCR also supports the inhibitory activity of the identified peptides, where P51 and P52 significantly inhibit the inductive effect of TNF-? on I?B-? mRNA levels. The inhibitory effects of the peptides were attributed to their abilities of binding at the inter-subunit interfaces leading to TNF-? dissociation. The results of molecular docking studies revealed that the peptides-TNF-? complexes are mostly stabilized by hydrophobic contacts. é 2016 Elsevier B.V. | |
dc.language.iso | English | |
dc.relation.ispartof | European Journal of Pharmaceutical Sciences | |
dc.subject | I kappa B alpha | |
dc.subject | messenger RNA | |
dc.subject | protein p51 | |
dc.subject | protein p52 | |
dc.subject | tumor necrosis factor | |
dc.subject | peptide | |
dc.subject | peptide library | |
dc.subject | protein binding | |
dc.subject | tumor necrosis factor | |
dc.subject | animal cell | |
dc.subject | Article | |
dc.subject | computer model | |
dc.subject | concentration (parameters) | |
dc.subject | controlled study | |
dc.subject | cytotoxicity | |
dc.subject | dissociation | |
dc.subject | drug binding | |
dc.subject | drug identification | |
dc.subject | IC50 | |
dc.subject | L929 cell line | |
dc.subject | molecular docking | |
dc.subject | nonhuman | |
dc.subject | phage display | |
dc.subject | priority journal | |
dc.subject | animal | |
dc.subject | antagonists and inhibitors | |
dc.subject | cell surface display | |
dc.subject | chemical model | |
dc.subject | chemistry | |
dc.subject | computer simulation | |
dc.subject | genetics | |
dc.subject | human | |
dc.subject | Jurkat cell line | |
dc.subject | metabolism | |
dc.subject | mouse | |
dc.subject | peptide library | |
dc.subject | physiology | |
dc.subject | procedures | |
dc.subject | protein secondary structure | |
dc.subject | protein tertiary structure | |
dc.subject | Animals | |
dc.subject | Cell Surface Display Techniques | |
dc.subject | Computer Simulation | |
dc.subject | Humans | |
dc.subject | Jurkat Cells | |
dc.subject | Mice | |
dc.subject | Models, Chemical | |
dc.subject | Peptide Library | |
dc.subject | Peptides | |
dc.subject | Protein Binding | |
dc.subject | Protein Structure, Secondary | |
dc.subject | Protein Structure, Tertiary | |
dc.subject | Tumor Necrosis Factor-alpha | |
dc.title | Identification of novel peptides against TNF-? using phage display technique and in silico modeling of their modes of binding | |
dc.type | Article | |
dc.citation.volume | 96 | |
dc.citation.spage | 490 | |
dc.citation.epage | 498 | |
dc.citation.index | Scopus | |
dc.identifier.DOI | https://doi.org/10.1016/j.ejps.2016.10.005 | |